EMERGENT BIOSOLUTIONS INC. Acquisitions, Net of Cash Acquired
EMERGENT BIOSOLUTIONS INC. (EBS) reported Acquisitions, Net of Cash Acquired of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-19.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2021-02-19
- EMERGENT BIOSOLUTIONS INC. payments to acquire businesses, net of cash acquired for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. payments to acquire businesses, net of cash acquired for the quarter ending 2015-12-31 was $650.00K, a 46.37% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. payments to acquire businesses, net of cash acquired for the quarter ending 2015-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments to acquire businesses, net of cash acquired for the quarter ending 2015-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments to acquire businesses, net of cash acquired for fiscal 2020 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments to acquire businesses, net of cash acquired for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- EMERGENT BIOSOLUTIONS INC. payments to acquire businesses, net of cash acquired for fiscal 2018 was $827.70M, a 604.43% increase from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. payments to acquire businesses, net of cash acquired for fiscal 2017 was $117.50M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 12 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-19 | |||||
| 2019-12-31 | $0.00 10-K · filed 2021-02-19 | |||||
| 2018-12-31 | $827.70M 10-K · filed 2021-02-19 | |||||
| 2017-12-31 | $117.50M 10-K · filed 2020-02-25 | $195.10M 10-K · filed 2018-02-23 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 10-K · filed 2019-02-22 | ||||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-09 | |||||
| 2015-12-31 | $650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $650.00K derived: sum of 2 quarters · filed 2018-02-23 | $650.00K derived: sum of 3 quarters · filed 2018-02-23 | $650.00K 10-K · filed 2018-02-23 | ||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 derived: sum of 2 quarters · filed 2016-11-09 | $0.00 10-Q · filed 2016-11-09 | $1.21M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $0.00 10-Q · filed 2015-08-06 | $1.21M derived: sum of 3 quarters · filed 2017-02-28 | $1.21M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-08 | $1.21M derived: sum of 2 quarters · filed 2017-02-28 | $1.21M derived: sum of 3 quarters · filed 2017-02-28 | $1.21M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2014-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $1.21M derived: sum of 2 quarters · filed 2017-02-28 | $1.21M derived: sum of 3 quarters · filed 2017-02-28 | $179.38M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $0.00 derived: sum of 2 quarters · filed 2015-11-06 | $178.17M 10-Q · filed 2015-11-06 | $204.04M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $178.17M 10-Q · filed 2015-08-06 | $204.04M derived: sum of 3 quarters · filed 2016-02-29 | $204.04M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-03-31 | $178.17M 10-Q · filed 2015-05-08 | $204.04M derived: sum of 2 quarters · filed 2016-02-29 | $204.04M derived: sum of 3 quarters · filed 2016-02-29 | $204.04M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $25.87M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $25.87M derived: sum of 2 quarters · filed 2016-02-29 | $25.87M derived: sum of 3 quarters · filed 2016-02-29 | $25.87M 10-K · filed 2016-02-29 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $0.00 derived: sum of 2 quarters · filed 2014-11-10 | $0.00 10-Q · filed 2014-11-10 | $24.12M 10-Q · filed 2013-11-08 | $0.00 derived: sum of 4 quarters · filed 2015-03-09 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $0.00 10-Q · filed 2014-08-08 | $0.00 derived: sum of 3 quarters · filed 2015-03-09 | |||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-12 | $0.00 derived: sum of 2 quarters · filed 2015-03-09 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $0.00 10-K · filed 2015-03-09 | ||||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-08 | |||||
| 2011-12-31 | $0.00 10-K · filed 2014-03-10 | |||||
| 2010-12-31 | $17.87M 10-K · filed 2013-03-08 | |||||
| 2009-12-31 | $0.00 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |